GLP-1s and Hair Loss: Rapid Weight Loss, Not the Drug, Is the Culprit

Last Updated: MARCH 2026

The prospect of hair loss can be distressing, especially when embarking on a journey to improve health with GLP-1 medications like Wegovy or Zepbound. Clinical trial data shows a clear increase in reported alopecia among patients taking these drugs compared to placebo. For instance, in trials for semaglutide (Wegovy), alopecia was reported in 2.3% of participants, compared to 1.0% for placebo. For tirzepatide (Zepbound), the incidence was higher at 5.7% versus 1.0% for placebo. The evidence strongly suggests this hair shedding is not a direct drug side effect, but rather a consequence of the rapid and significant weight loss these medications facilitate.

This temporary hair loss, known as telogen effluvium, is a well-documented physiological response to major bodily stress. While the numbers can seem concerning, understanding the mechanism behind this phenomenon can provide clarity and perspective.

What is Telogen Effluvium?

Telogen effluvium (TE) is a common cause of temporary hair shedding characterized by a premature shift of a large number of growing hair follicles (anagen phase) into the resting phase (telogen phase). Normally, about 85-90% of your hair is in the anagen phase, and 10-15% is in the telogen phase. With TE, this ratio shifts, leading to increased shedding.

This process is typically triggered by a significant physical or psychological stressor on the body. Common triggers include:

• Rapid or significant weight loss (regardless of method)
• Major surgery or illness
• Childbirth
• Severe psychological stress
• Nutritional deficiencies
• Certain medications

The shedding usually begins about two to four months after the stressful event and can last for several months. For most individuals, telogen effluvium resolves on its own as the body adapts and the hair growth cycle normalizes.

Hair Loss Incidence in GLP-1 Clinical Trials

The prescribing information for both Wegovy (semaglutide) and Zepbound (tirzepatide) lists alopecia as an adverse reaction observed in clinical trials. The rates, while higher than placebo, are generally low.

The U.S. Food and Drug Administration (FDA) prescribing information for Wegovy states, “The most commonly reported adverse reactions [in the semaglutide group] were nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and alopecia.” It further specifies an incidence of 2.3% for alopecia in the semaglutide group versus 1.0% in the placebo group.

Similarly, for Zepbound, the FDA prescribing information indicates an even higher, though still modest, incidence: “Alopecia occurred in 5.7% of Zepbound-treated patients compared to 1.0% of placebo-treated patients.”

Here’s a comparison of alopecia incidence in the pivotal trials for the leading GLP-1 weight loss medications:

These figures highlight that while hair loss is more common in individuals taking these medications, a baseline level of hair loss also occurs in the general population, as evidenced by the placebo groups. The increased percentage points, though small, are statistically significant.

The Connection to Rapid Weight Loss

The most compelling explanation for the increased incidence of hair loss among GLP-1 users is the rapid and substantial weight loss they experience. GLP-1 medications are highly effective at promoting significant weight reduction. For example, in the STEP 1 trial, participants on semaglutide achieved an average weight loss of 14.9% of their body weight over 68 weeks, compared to 2.4% for placebo. The SURMOUNT-1 trial saw even greater efficacy, with tirzepatide leading to average weight reductions of up to 20.9% at the highest dose.

This magnitude and speed of weight loss can be perceived by the body as a significant physiological stressor, triggering telogen effluvium. It’s a phenomenon well-documented in other rapid weight loss scenarios, such as bariatric surgery patients or individuals following very low-calorie diets. A study on bariatric surgery patients, for example, noted that “hair loss (telogen effluvium) is a common complication after bariatric surgery, occurring in 40–60% of patients” and is often linked to the rapid weight loss phase.

The consensus among medical experts is that GLP-1 medications do not directly cause hair loss through a unique pharmacological mechanism. Instead, they facilitate a physiological state—rapid weight loss—that is a known trigger for telogen effluvium. The hair follicles, under stress from the rapid metabolic changes and nutrient demands associated with significant weight reduction, temporarily halt growth and enter a shedding phase.

What to Expect and How to Address It

Hair loss due to telogen effluvium is typically temporary. The shedding phase usually lasts a few months, after which the hair growth cycle normalizes. Regrowth often becomes noticeable within six to nine months as the body adjusts to its new weight and metabolic state.

While GLP-1 medications are potent tools for weight management, maintaining adequate nutrition is crucial during periods of rapid weight loss. Ensuring sufficient intake of protein, vitamins, and minerals can support overall hair health and mitigate potential deficiencies that might exacerbate shedding. Specifically, iron, zinc, biotin, and vitamins D and B complex are important for hair follicle function. If you are experiencing hair loss, it may be beneficial to discuss your nutritional intake with a healthcare provider.

It is also important to differentiate telogen effluvium from other forms of hair loss, such as androgenetic alopecia (pattern baldness) or alopecia areata, which have different underlying causes and treatments. Telogen effluvium typically presents as diffuse thinning across the scalp, rather than localized bald spots or receding hairlines.

In conclusion, the increased incidence of hair loss reported in GLP-1 clinical trials is a real effect, but the evidence points strongly to rapid weight loss as the primary underlying cause. This is a temporary condition for most, and hair regrowth typically occurs as the body adapts to its new metabolic equilibrium.

Sources

1. U.S. Food and Drug Administration. (2021). Wegovy (semaglutide) Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
2. U.S. Food and Drug Administration. (2023). Zepbound (tirzepatide) Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217772s000lbl.pdf
3. Livingstone, S., & Booth, M. M. (2022). Hair Loss (Telogen Effluvium) After Bariatric Surgery: An Up-to-Date Overview. Obesity Surgery, 32(3), 1017–1025. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945763/